Iluvien (Fluocinolone Acetonide)

Fluocinolone acetonide binds to intracellular glucocorticoid receptors, modulating gene transcription to suppress inflammatory cytokines, inhibit angiogenesis, and reduce vascular permeability. By stabilising the blood‑retinal barrier, it decreases fluid leakage from retinal vessels, thereby reducing macular edema and controlling intra‑ocular inflammation.

The dosing regimen for Iluvien is determined by the prescribing ophthalmologist. Each implant contains a fixed 0.19 mg of fluocinolone acetonide and is inserted once into the vitreous cavity. The clinician decides the timing of implantation based on the patient’s disease status and prior response to corticosteroids.

The safety of Iluvien during pregnancy or lactation has not been established. Because the product delivers a corticosteroid directly to the eye, systemic exposure is minimal, but the potential risk cannot be ruled out. Physicians should weigh the benefits against possible risks and consider alternative treatments for pregnant or nursing patients.

To request Iluvien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

The primary alternative to Iluvien is the dexamethasone intravitreal implant (Ozurdex) and anti‑VEGF agents. Iluvien offers a longer duration of action—up to 36 months—whereas dexamethasone typically lasts 3–6 months and requires more frequent re‑injection. Anti‑VEGF drugs target vascular endothelial growth factor rather than inflammation, making Iluvien preferable for patients whose edema is driven primarily by inflammatory pathways.

Iluvien should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the implant from moisture, direct sunlight, and physical damage. Do not refrigerate or freeze the device. Prior to implantation, the product should be inspected for integrity and handled in a sterile ophthalmic environment.

Iluvien is implanted by a qualified ophthalmic surgeon using a specialized intravitreal delivery system. The procedure is performed in an operating‑room setting under aseptic conditions. The implant is inserted through the pars plana into the vitreous cavity, where it releases fluocinolone acetonide slowly over several years.

The most serious risks include elevated intra‑ocular pressure that may require medication or surgery, cataract formation that can necessitate extraction, and endophthalmitis—a severe intra‑ocular infection that requires immediate treatment. Patients should be monitored regularly for these complications, and any sudden visual changes should prompt urgent ophthalmic evaluation.

Iluvien is contraindicated in patients with active ocular infection, uncontrolled glaucoma, or a history of steroid‑induced intra‑ocular pressure spikes that are unmanageable. It should also be avoided in individuals with known hypersensitivity to fluocinolone acetonide or any component of the implant. Careful assessment is required before implantation.